替莫唑胺联合放疗与尼莫司汀联合放疗安全性及疗效的比较

目的:比较替莫唑胺和尼莫司汀联合放疗对高度恶性胶质瘤术后治疗的疗效及安全性。方法:选择2008年2月到2009年4月收治的术后病理证实为高度恶性胶质瘤患者43例,随机分为两组,实验组20例,在放疗同时采用替莫唑胺化疗;对照组23例,在放疗同时采用尼莫司汀化疗。长期随访,观察患者的有效率、6个月无疾病进展生存率、1年无疾病进展生存率及不良反应发生的情况。结果:实验组在1年无疾病进展生存率70%,明显高于对照组34.78%(P<0.05);实验组有效率55%,明显高于对照组有效率26.08%;实验组不良反应发生率低,毒副反应轻。结论:替莫唑胺联合放疗治疗高度恶性胶质瘤效果明显优于尼莫司汀联合放疗,副反应轻,患者耐受性好。

Objective To compare the clinical toxicity and efficacy of Temozolomide injection combined with concurrent radiotherapy with the clinical toxicity and efficacy of Nimustine injection combined with concurrent radiotherapy in the post-operative treatment of high-grade glioma（HGG）. Methods 43 patients who have been proved to be with high-grade glioma by post-operative Pathological test were randomized into two groups, the experimental group with 20 patients received radiotherapy combined with concurrent chemotherapy of Temozolomide injection; the control group with 23 patients received radiotherapy combined with concurrent chemotherapy of Nimustine injection. Carrying out a long-term follow-up to evaluate the effective power, survival rate, 1-year progression-free survival rate and adverse effect. Results 1-year progression-free survival rate（70% ）in the experimental group is apparently higher than in the control group（34.78%） （P〈0.05）; The effective power of experimental group（55%）is apparently higher than the control group（26.08% ）; The adverse effect in the experimental group is low, and the toxicity is slight. Conclusion The effect of Temozolomide injection combined with concurrent radiotherapy in the treatment of high-grade glioma is apparently better than Nimustine injection combined with concurrent radiotherapy.